Bennekers J H, van Mechelen R, Meijer A
Neth Heart J. 2004 Oct;12(10):450-454.
To prove that long-distance running is safe for athletes with pacemaker devices, pacemaker function was evaluated in nine long-distance runners.
Nine runners participated in a nine-month training programme that involved running for 1000 or 2000 km in preparation for either a full or a half marathon. A professional coach, three cardiologists and a technician - all with running experience - conducted the training and medical checkups. Commercial heart rate monitors were used during training to assess heart rates at rest, and during exercise and long-distance running. Sensing and pacing functions of the pacemaker system were tested during training sessions as well as during the race. In addition, the ChampionChip (a time registration device used in competition) and the Polar heart rate monitor (a widely used self-monitoring device) were tested for possible interference with the pacemaker.
All nine athletes completed the Amsterdam 2001 half or full marathon without any pacemaker dysfunction. A short survey after two years showed no pacemaker dysfunction.
Long-distance running is safe for athletes with pacemaker implants. Overall fitness and sufficient endurance training remain the prerequisites for maintaining the condition necessary for successful completion of a marathon regardless of medical status. In our study, it became clear that for patients who had received a pacemaker because of complete heart block, the upper rate of the pacemaker programme needed to be adjusted to 170 to 180 ppm to insure 1:1 atrio-ventricular synchrony during high atrial rates. It is concluded that there is reason for cardiologists to advise against long-distance running in athletes with pacemakers. Patients with known or suspected structural heart disease should be screened according the recommendations.
为证明长跑对植入起搏器的运动员是安全的,对9名长跑运动员的起搏器功能进行了评估。
9名跑步者参加了为期9个月的训练计划,为全程或半程马拉松做准备,期间跑步1000或2000公里。一名专业教练、三名心脏病专家和一名技术人员——均有跑步经验——进行训练和医学检查。训练期间使用商用心率监测仪评估静息心率、运动中和长跑时的心率。在训练期间以及比赛期间测试起搏器系统的感知和起搏功能。此外,还测试了冠军芯片(比赛中使用的计时设备)和极地心率监测仪(一种广泛使用的自我监测设备)对起搏器的可能干扰。
所有9名运动员均完成了2001年阿姆斯特丹半程或全程马拉松,且无任何起搏器功能障碍。两年后的一项简短调查显示无起搏器功能障碍。
长跑对植入起搏器的运动员是安全的。无论健康状况如何,总体健康状况和足够的耐力训练仍然是维持成功完成马拉松所需条件的前提。在我们的研究中,很明显,对于因完全性心脏传导阻滞而植入起搏器的患者,起搏器程序的上限频率需要调整到170至180次/分钟,以确保在高心房率时房室1:1同步。结论是,心脏病专家没有理由建议植入起搏器的运动员不要长跑。已知或疑似患有结构性心脏病的患者应根据建议进行筛查。